Pharma versus coronavirus: interviews with General Directors 

General Directors of the leading companies on the market have discussed with the Russian Pharmaceutical Forum the main challenges they are facing during the pandemic, and possible approaches to collaborating with the government on developing both a vaccine and treatments for COVID-19. 

The SARS-CoV-2 coronavirus pandemic has kicked the rate of development in the pharmaceutical industry into a new gear. At the early stages of the epidemic in Russia, the demand for medical masks, antiseptics and antivirals soared. A series of regulatory decisions followed, taken at an unprecedented speed, outlining a new set of rules for maximum retail prices and distance selling of medical products. 

The pharmaceutical industry is undergoing enormous change fuelled by a global crisis in healthcare. But pharma also has a key role to play in the search for ways out of the current situation. 

READ OUR PHRAMACEUTICAL BLOG>>

• Seeking solutions to the critical healthcare problems in Russia
• Analysis of the key regulatory changes affecting pharmaceutical industry
• COVID-19 pandemic: the response of the Russian pharmaceutical market
• Drug pricing methodologies aimed at stimulating innovation
• Drug labelling - success stories and implementation case studies
• Public procurement optimisation and the formation of the Essential and Vital Drug List
• How to ensure access to innovative treatments on the Russian market?
• International drug R&D innovation implementation practices
• Common Eurasian Economic Union drug market - next steps in regulatory harmonisation
• Evolution in the producer - distributor - retailer dynamics
• Sales trends, purchasing power and consumer demand forecasts
• Developing local active pharmaceutical substance production market
• Medicine of the future: genomics, biotechnologies, personalised medicine

• Digital healthcare: telemedicine today and in the future
• IT trends: mobile technologies, the Internet of Things, blockchain in pharma
• Big data and artificial intelligence in drug development and diagnostics
• Data-centric marketing and data analytics for strategic planning
• Smart technologies and innovation in drug manufacturing
• New business models and online retail: consumer market transformation
• Skill crisis: how to secure highly competent staff for your business?
• Analytics, opportunities to share best practice, success stories from top pharma leaders